The Thoc1 Ribonucleoprotein as a Novel Biomarker for Prostate Cancer Treatment Assignment
Technical Report,15 Sep 2016,14 Sep 2017
Health Research, Inc. Buffalo United States
Pagination or Media Count:
Active surveillance AS is an option for men with low risk prostate cancer in order to reduce over treatment, but few men choose it because current prognostic indicators are imperfect. The objectives of this research are to test whether pThoc1 can improve the assignment of prostate cancer patients to therapy. We have made significant progress on the goals articulated in the Statement of Work. IRBHRPO approval has been obtained for construction and use of new TMAs PI Mohler and Goodrich. The TMAs from PCaP have been obtained PI Mohler and Goodrich. Pathology analysis of 1146 patient specimens is complete and construction of TMAs is complete PI Mohler. Immunostaining of all TMAs is complete PI Goodrich. IRBHRPO approval for active surveillance specimens has been obtained PI Mohler, Goodrich. Enrollment of prostate cancer patients on active surveillance is ongoing PI Mohler. Immunostaining of prostate cancer biopsy specimen of patients who qualified for active surveillance is complete PI Goodrich. ELISA assay development for measuring pThoc1 and pThoc1 autoantibodies is complete PI Goodrich. IRBHRPO approval for serum samples has been obtained PI Mohler, Goodrich. Analysis of serum samples from prostate cancer patients of PCaP cohort is complete PI Goodrich. Analysis of serum samples from prostate cancer patients and corresponding normal subjects of RPCI cohort has been initiated PI Goodrich. Year 4 of the grant will finish data acquisition and data analysis. Over treatment complicates the clinical management of prostate cancer. Improving the ability to distinguish aggressive from indolent disease is recognized as an unmet need by the 2013 PCRP Overarching Challenges.
- Medicine and Medical Research